BJMO - volume 8, issue 1, march 2014
D. Lossignol
Morphine, and derivatives, remain the cornerstone of cancer pain management. They share the same clinical spectrum but exhibit different pharmacological profiles. Some derivatives have specificity regarding pain control (i.e. neuropathic pain) potency or toxicity. The interest of having different opioids relies in part on inter-individual genetic variability (in terms of metabolism or receptor affinity). The specificity of breakthrough pain syndrome is considered. Because of various available converting ratio, a simplified converting table is proposed.
(BELG J MED ONCOL 2014;8(1):9–13)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
